Bio-Path Holdings

Bio-Path is a publicly traded biotechnology company focused on developing therapeutic products utilizing its proprietary liposomal delivery technology designed to distribute nucleic acid drugs throughout the human body with a simple intravenous infusion. The Company’s initial focus is on cancer. Bio-Path’s lead product candidate, BP1001 (Liposomal Grb-2), is completing the safety segment of the Phase II for AML in combination with the frontline therapy for induction therapy ineligible patients. A second Phase II safety segment for CML will start in the first half of 2016. Bio-Path’s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors. Bio-Path's antisense DNA - liposomal delivery technology is called DNAbilize™ and is available for licensing for drug development. DNAbilize™ offers distinct advantages over the current antisense and RNAi therapeutics in development. DNAbilize™ chemistry has shown no toxicity in patients to date. This allows for higher dosing to a therapeutic level compared to the more toxic approaches including phosphorothioate DNA. DNAbilize™ also has the advantage of systemic distribution and allows for targeting genes involved in diseases beyond the liver. Systemic level diseases and disorders can be targeted using DNAbilize™. We are interested in collaborations to develop therapeutics using DNAbilize.
Company Growth (employees)
Type
Public
HQ
Bellaire, US
Founded
2011
Size (employees)
11 (est)
Bio-Path Holdings was founded in 2011 and is headquartered in Bellaire, US

Bio-Path Holdings Office Locations

Bio-Path Holdings has office in Bellaire
Bellaire, US

Bio-Path Holdings Metrics

Bio-Path Holdings Summary

Market capitalization

$78.4 m

Closing share price

$0.8
Bio-Path Holdings's current market capitalization is $78.4 m.

Bio-Path Holdings Financials

Bio-Path Holdings's revenue is $0 in FY, 2013 which is a NaN% decrease from the previous period.
FY, 2013FY, 2014FY, 2015Y, 2016

Revenue

$13 k

Revenue growth, %

NaN%NaN%

Operating expense total

$15.7 m$4.5 m$5.5 m

EBIT

($15.7 m)($4.5 m)($5.5 m)

Net Income

($15.4 m)($4.5 m)($5.5 m)

Operating cash flow

$3.6 m$10.3 m($5 m)

Bio-Path Holdings Market Value History

We estimate that Bio-Path Holdings's current employees are approximately 22% female and 78% male.

Bio-Path Holdings News

Bio-Path Holdings Company Life

You may also be interested in